GHRP-6 Side Effects

Reported GHRP-6 side effects

Very Common (expected in most users) Strong appetite stimulation / hunger — The signature effect of GHRP-6, noticeable within 30-60 minutes of injection. For users in caloric surplus, this is often welcome. For users in deficit, this is frequently the primary reason to switch to GHRP-2 or ipamorelin. Injection site reactions — Mild erythema, transient itching at SC injection site. Rotating sites minimizes. Flushing — Pink/red flush of face and neck post-injection, fading in 15-30 minutes. Vivid dreams — Commonly reported with bedtime dosing; associated with enhanced slow-wave sleep. Common Transient cortisol elevation — +15-25% above baseline for 60-90 minutes post-injection. Similar to GHRP-2. Usually clinically trivial in healthy users but relevant in users with HPA axis concerns, anxiety disorders, or adrenal insufficiency. Mild prolactin elevation — Usually clinically trivial but relevant in users with baseline prolactin-sensitive conditions. Mild fluid retention — Particularly first 2-3 weeks of daily use. Self-limiting. Transient insulin sensitivity reduction — GH-axis stimulation modestly reduces insulin sensitivity over time. Monitor HbA1c and fasting insulin in extended use. Mild headache — Uncommon; typically responsive to hydration. Less Common Nausea — More common with high doses (>300 mcg) or IV administration. Rare at standard SC doses. Transient hypotension — Primarily with IV administration; SC route rarely produces meaningful blood pressure effects. Paresthesia / scalp tingling — Transient, benign. Dysgeusia — Unusual taste immediately post-injection. Dose-Dependent with Long-term Use Weight gain — Not the GH-mediated lean mass gain but actual weight gain from sustained appetite stimulation if caloric intake is not managed. Users consistently report the need for disciplined meal planning to prevent overshooting intended calories. Insulin resistance — Modest but measurable with chronic daily high-dose use over months. HbA1c monitoring at 3-month intervals is reasonable. GHS-R1a receptor desensitization — Chronic high-frequency dosing produces measurable tachyphylaxis. Cycling (5 on / 2 off weekly, or 8 on / 2 off macro) helps maintain responsiveness. Cumulative HPA axis effects — Repeated low-grade cortisol elevation over months could theoretically contribute to dysregulation in susceptible users. Theoretical Long-term Concerns Like all GH-axis interventions, sustained IGF-1 elevation raises theoretical concerns around chronic mitogenic signaling and cancer risk. No causal link has been demonstrated, but mechanistic plausibility supports conservative dosing, periodic IGF-1 monitoring, and avoidance in users with active malignancy or strong family history of hormonally-responsive cancers. Signs You Are Overdosing Persistent joint discomfort or peripheral edema Carpal tunnel symptoms Persistent fasting glucose elevation (>110 mg/dL) Unexpected weight gain beyond what your caloric intake accounts for Sleep apnea worsening Any of these warrant dose reduction or discontinuation.

When to continue, reduce, or stop GHRP-6

GHRP-6 contraindications

GHRP-6 is contraindicated or requires extreme caution in: Active malignancy — particularly hormone-responsive cancers; IGF-1 elevation theoretical tumor-promotion risk Strong family history of GH-axis sensitive cancers — specialist supervision required Pregnancy and lactation — no established safety data Known hypersensitivity to GHRP-6, related hexapeptides, or any excipient Severe untreated obstructive sleep apnea — theoretical concern about airway soft-tissue growth; stabilize with CPAP/APAP first Acute critical illness — GH-axis stimulation inappropriate during sepsis, post-surgical recovery, multiple trauma, or respiratory failure Diabetic ketoacidosis or severe uncontrolled diabetes — resolve metabolic state first Active proliferative retinopathy — relative contraindication Hypothalamic-pituitary disease with untreated adrenal insufficiency — the residual cortisol effect may be unreliable; specialist supervision required Prolactinoma or clinically significant hyperprolactinemia — the modest prolactin elevation could complicate management Binge eating disorder, bulimia, or other active eating disorders — the appetite-stimulating effect is contraindicated given the underlying pathology Relative cautions (monitor closely): Borderline fasting glucose or elevated HbA1c — GH-axis effects tip toward insulin resistance Cushing's syndrome or baseline elevated cortisol — GHRP-6 adds to HPA load Anxiety disorders or HPA axis dysregulation — cortisol elevation may be poorly tolerated Uncontrolled GERD / reflux disease — ghrelin-receptor agonism stimulates gastric motility and acid secretion; symptoms may worsen Active weight-loss phase — directly opposed to GHRP-6's appetite effect; consider alternatives Concurrent GLP-1 agonist therapy — actively opposing appetite signals; defeats the goals of both Strong family history of colon polyps — baseline colonoscopy before starting Concurrent glucocorticoid therapy — pharmacodynamic interference Drug interactions: Glucocorticoids: Reduced GH response; pharmacodynamic interference GLP-1 receptor agonists: Directly opposing appetite pharmacology; defeats the purpose of both Opioids: Can augment the cortisol and prolactin effects of GHRP-6 Thyroid hormone replacement: GH-axis changes can alter thyroid requirements; monitor TSH periodically Exogenous GH: Pharmacologically counterproductive; the combination is pointless Discontinuation triggers: Persistent joint pain, carpal tunnel symptoms, or peripheral edema Persistent fasting glucose >110 mg/dL Cushingoid body composition changes (buffalo hump, moon face, central obesity beyond baseline) Worsening sleep apnea Unexpected weight gain beyond managed caloric intake Development of eating disorder patterns or loss of control around food Any cardiovascular symptoms

Why vendor quality drives GHRP-6 side-effect frequency

Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.

GHRP-6 side effects FAQ

Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .